Background: Skull base paragangliomas (SBP) are locally expansile tumors that can be treated with stereotactic radiotherapy with favorable results. This report describes the results of 31 patients with SBP treated with CyberKnife radiotherapy delivering a total dose of 25 Gray in five fractions. Methods: All patients treated with five-fraction CyberKnife radiotherapy at a single institution were identified between 2007 and 2013. Tumor volumetric analyses were performed to assess responses to radiotherapy. Results: Median follow-up was 24 months with a range of 4-78 months. Local control and overall survival were 100%. Of the 20 patients who presented with tinnitus, 12 reported improvement (60%), of whom 6 reported complete resolution. There was a 37.3% reduction in tumor volume among all patients (p = 0.16). On subset analysis of patients with ≥24 months of follow-up, tumor volume decreased 49% (p = 0.01). The rate of grade 1-2 toxicity was 19%, with no grade 3 or worse toxicity. Conclusion: A five-fraction CyberKnife-based stereotactic radiotherapy approach is safe and efficacious for the management for patients with SBP. Our findings suggest the potential use of this strategy as a definitive or salvage treatment option for SBP.

Keywords:
Paraganglioma, Glomus tumor, CyberKnife, Radiation therapy, Glomus jugulare, Glomus jugulotympanicum, Stereotactic body radiation therapy
1.
Al-Mefty O, Teixeira A: Complex tumors of the glomus jugulare: criteria, treatment, and outcome. J Neurosurg 2002;97:1356-1366.
2.
Chretien PB, Engelman K, Hoye RC, Geelhoed GW: Surgical management of intravascular glomus jugulare tumor. Am J Surg 1971;122:740-743.
3.
Forbes JA, Brock AA, Ghiassi M, Thompson RC, Haynes DS, Tsai BS: Jugulotympanic paragangliomas: 75 years of evolution in understanding. Neurosurg Focus 2012;33: E13.
4.
Springate SC, Weichselbaum RR: Radiation or surgery for chemodectoma of the temporal bone: a review of local control and complications. Head Neck 1990;12:303-307.
5.
Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Antonelli PJ, Cassisi NJ: Definitive radiotherapy in the management of chemodectomas arising in the temporal bone, carotid body, and glomus vagale. Head Neck 2001;23:363-371.
6.
Guss ZD, Batra S, Limb CJ, et al: Radiosurgery of glomus jugulare tumors: a meta-analysis. Int J Radiat Oncol Biol Phys 2011;81:e497-e502.
7.
Larner JM, Hahn SS, Spaulding CA, Constable WC: Glomus jugulare tumors: long-term control by radiation therapy. Cancer 1992;69:1813-1817.
8.
Sheehan JP, Tanaka S, Link MJ, et al: Gamma Knife surgery for the management of glomus tumors: a multicenter study. J Neurosurg 2012;117:246-254.
9.
Sheehan J, Kondziolka D, Flickinger J, Lunsford LD: Gamma knife surgery for glomus jugulare tumors: an intermediate report on efficacy and safety. J Neurosurg 2005;102(suppl):241-246.
10.
Wegner RE, Rodriguez KD, Heron DE, Hirsch BE, Ferris RL, Burton SA: Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. Radiother Oncol 2010;97:395-398.
11.
Lim M, Bower R, Nangiana JS, Adler JR, Chang SD: Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat 2007;6:419-423.
12.
Lim M, Gibbs IC, Adler JR Jr, Chang SD: Efficacy and safety of stereotactic radiosurgery for glomus jugulare tumors. Neurosurg Focus 2004;17:E11.
13.
Lim M, Gibbs IC, Adler JR Jr, Martin DP, Chang SD: The efficacy of linear accelerator stereotactic radiosurgery in treating glomus jugulare tumors. Technol Cancer Res Treat 2003;2:261-265.
14.
Bianchi LC, Marchetti M, Brait L, et al: Paragangliomas of head and neck: a treatment option with CyberKnife radiosurgery. Neurol Sci 2009;30:479-485.
15.
Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ: Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. J Clin Oncol 2014;32:841-850.
16.
Basch E, Iasonos A, McDonough T, et al: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006;7:903-909.
17.
Liu YJ, Zhu GP, Guan XY: Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 2012;48:554-559.
18.
Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
19.
Nakamura JL, Verhey LJ, Smith V, et al: Dose conformity of gamma knife radiosurgery and risk factors for complications. Int J Radiat Oncol Biol Phys 2001;51:1313-1319.
20.
Golanov AV, Kapitanov DN, Pronin IN, et al: First experience of CyberKnife stereotactic radiotherapy for glomus jugulare tumors (in Russian). Zh Vopr Neirokhir Im N N Burdenko 2012;76:30-36; discussion 36.
21.
Wennberg BM, Baumann P, Gagliardi G, et al: NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol 2011;50:518-527.
22.
Liscak R, Vladyka V, Wowra B, et al: Gamma Knife radiosurgery of the glomus jugulare tumour - early multicentre experience. Acta Neurochir 1999;141:1141-1146.
23.
Liscak R, Vladyka V, Simonova G, Vymazal J, Janouskova L: Leksell gamma knife radiosurgery of the tumor glomus jugulare and tympanicum. Stereotact Funct Neurosurg 1998;70(suppl 1):152-160.
24.
Sharma MS, Gupta A, Kale SS, Agrawal D, Mahapatra AK, Sharma BS: Gamma knife radiosurgery for glomus jugulare tumors: therapeutic advantages of minimalism in the skull base. Neurol India 2008;56:57-61.
25.
Genc A, Bicer A, Abacioglu U, Peker S, Pamir MN, Kilic T: Gamma knife radiosurgery for the treatment of glomus jugulare tumors. J Neurooncol 2010;97:101-108.
26.
Gerosa M, Visca A, Rizzo P, Foroni R, Nicolato A, Bricolo A: Glomus jugulare tumors: the option of gamma knife radiosurgery. Neurosurgery 2006;59:561-569; discussion 561-569.
27.
Raquet F, Mann W, Amedee R, Maruer J, Gilsbach J: Functional deficits of cranial nerves in patients with jugular foramen lesions. Skull Base Surg 1991;1:117-119.
28.
Sanna M, Bacciu A, Falcioni M, Taibah A: Surgical management of jugular foramen schwannomas with hearing and facial nerve function preservation: a series of 23 cases and review of the literature. Laryngoscope 2006;116:2191-2204.
29.
Oghalai JS, Leung MK, Jackler RK, McDermott MW: Transjugular craniotomy for the management of jugular foramen tumors with intracranial extension. Otol Neurotol 2004;25:570-579; discussion 579.
30.
Green JD Jr, Brackmann DE, Nguyen CD, Arriaga MA, Telischi FF, De la Cruz A: Surgical management of previously untreated glomus jugulare tumors. Laryngoscope 1994;104:917-921.
31.
Jackson CG, McGrew BM, Forest JA, Netterville JL, Hampf CF, Glasscock ME 3rd: Lateral skull base surgery for glomus tumors: long-term control. Otol Neurotol 2001;22:377-382.
32.
Ivan ME, Sughrue ME, Clark AJ, et al: A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors. J Neurosurg 2011;114:1299-1305.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.